ArticleFrontiers in oncology2025
Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the therapeutic efficacy and adverse effects of combining enzalutamide with docetaxel versus using docetaxel alone in treating metastatic castration-resistant prostate cancer (mCRPC) that progresses after treatment with abiraterone followed by enzalutamide. Methods: A retrospective analysis involved 67 mCRPC patients at the First Affiliated Hospital of Soochow University's Urology Department between October 2021 and August 2023. All experienced disease progression after treatment with abiraterone and enzalutamide. Patients were either in the study group, receiving enzalutamide and docetaxel, or in the control group, treated with docetaxel alone. Prostate-specific antigen (PSA) levels, imaging changes, and common adverse reactions were compared. Results: The study group showed a more significant reduction in PSA levels (≥50%) and improved outcomes in bone and lymph node metastases than the control group (P < 0.05). The median PSA progression-free survival (PFS) was longer for the study group at 193 days (95% CI: 174-207) versus 127 days (95% CI: 114-160) for the control group. Similarly, the median PFS for bone metastases was 271 days (95% CI: 265-274) in the study group, compared to 185 days (95% CI: 183-265) in the control group. For lymph node metastases, PFS was 265 days (95% CI: 194-274) versus 183 days (95% CI: 180-189), respectively, all statistically significant (P < 0.05). Visual analog scale scores decreased significantly post-treatment in both groups (P < 0.05), with more pronounced pain relief in the study group; median scores were 2 (IQR, 1-3) versus 3 (IQR, 3-5; P < 0.05). No Grade 3 or higher adverse reactions occurred, although the study group had more malaise, lumbago, and backache (P < 0.05). There were no significant differences in myelosuppression, gastrointestinal issues, liver dysfunction, neurological symptoms, edema, rash, or high blood pressure between groups (P > 0.05). Conclusion: Combining enzalutamide with docetaxel is more effective than docetaxel alone for treating mCRPC after abiraterone and enzalutamide, providing better PSA-PFS and improved metastasis outcomes, along with better pain relief. Though the combination resulted in more adverse effects, no severe reactions (Grade 3 or higher) were observed, indicating good tolerability and clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.